Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Private financings

    Global ambitions Private financings The average money raised by private European biotechs increased by 47% to $22.2 million in 2015 vs. $15.1 million in 2014; however, the amount still lags the $32 million average…

    Published on 5/16/2016
  • Figure: Public financings

    Global ambitions Public financings The top figure shows that the amount raised via equity financings by public European biotechs rose 1.7x to $8.1 billion in 2015 vs. a 1.4x increase in the U.S. to $24.3 billion. …

    Published on 5/16/2016
  • Figure: U.S. investors close the gap

    Global ambitions U.S. investors close the gap European-domiciled public companies that attracted U.S. investors through a U.S. listing raised nearly as much on average as public companies domiciled in the U.S. The…

    Published on 5/16/2016
  • Figure: U.S. VCs stepping up

    Global ambitions U.S. VCs stepping up The 15 U.S. VCs who invested in the greatest number of rounds worldwide during 2010-15 drove up the average round size compared with all European rounds. The average round for…

    Published on 5/16/2016
  • Table: New funds

    Global ambitions New funds Since the start of 2015, at least 31 life science funds with a European presence are raising or have raised a total of more than $8 billion. Funds are listed in descending order by size.…

    Published on 5/16/2016
  • Table: U.S. investment in top rounds

    Global ambitions U.S. investment in top rounds U.S. investors participated in at least seven of 10 European venture equity financings of $80 million or more since the start of 2015. Firms with headquarters in the U.…

    Published on 5/16/2016
  • Global ambitions

    Why European biotechs should start courting U.S. capital now

    European biotechs with the drive to compete on a global scale should start courting U.S. investors now, before the U.S. markets heat back up.

    Published on 5/16/2016
  • Table: Bugs as drugs

    Community organizers Bugs as drugs Selected companies developing pharmaceutical products that contain microbes as the active moiety. Excludes bacterial cancer vaccines, bacteriophages and bacteria engineered to …

    Published on 5/9/2016
  • Table: Traditional drugs from bugs

    Community organizers Traditional drugs from bugs Selected companies developing traditional drug therapeutics based on insights obtained from studying the microbiome. Excludes antibiotics and compounds that inhibit…

    Published on 5/9/2016
  • Getting into the game

    How pharmas are thinking about the microbiome for drug development

    A handful of pharmas are developing microbiome-targeted therapies; more are mining it for new targets and diagnostic insights.

    Published on 5/9/2016
  • Community organizers

    How studying bacteria by function is reshaping microbiome therapies

    The next wave of microbiome companies is opening up new mechanisms to treat disease by targeting or mimicking bacterial functions.

    Published on 5/9/2016
  • Figure: N = 1

    Don't skip DMD patients N = 1 Billy Ellsworth, one of the DMD patients who participated in the trial of Sarepta's eteplirsen, and CDER Director Janet Woodcock at the April 25 advisory committee meeting for …

    Published on 5/2/2016
  • Just to confirm

    How Sarepta's eteplirsen confirmatory trials could support full approval

    Sarepta's planned eteplirsen confirmatory studies could generate evidence to support full approval without exposing exon-51 patients to placebo.

    Published on 5/2/2016
  • Box: Few ripples

    Just to confirm Few ripples Accelerated approval of eteplirsen from Sarepta Therapeutics Inc. would be unlikely to greatly complicate development of other DMD treatments. Summit Therapeutics plc CEO Glyn Edwards …

    Published on 5/2/2016
  • Don't skip DMD patients

    Why FDA should grant accelerated approval to eteplirsen for DMD

    Eteplirsen should receive accelerated approval for DMD because patients have earned the right to make the risk-benefit decision.

    Published on 5/2/2016
  • Figure: PK picture

    Endangered TIGER? PK picture FDA's PK analysis of rociletinib from Clovis Oncology Inc. (NASDAQ:CLVS) found that increasing concentrations of the compound did not correlate with increases in objective response …

    Published on 4/25/2016
  • Figure: Rociletinib's history

    Endangered TIGER? Rociletinib's history Clovis Oncology Inc. (NASDAQ:CLVS) has flip-flopped on the target dose for rociletinib to treat non-small cell lung cancer (NSCLC) and, according to FDA, the agency has …

    Published on 4/25/2016
  • Table: Rociletinib safety

    Endangered TIGER? Rociletinib safety The rate of serious adverse events increased with higher doses of rociletinib from Clovis Oncology Inc. (NASDAQ:CLVS). Of particular concern for FDA and its Oncologic Drugs …

    Published on 4/25/2016
  • Endangered TIGER?

    Handicapping rociletinib's future in NSCLC

    The emerging NSCLC landscape and Clovis' history of ignoring regulators could scuttle any future path forward for rociletinib.

    Published on 4/25/2016
  • Can 'Cures' be cured?

    Assessing the prospects for Senate's 21st Century Cures bill

    Any 21st Century Cures bill that can get through Congress will not come close to radically transforming drug discovery or dramatically accelerating cures.

    Published on 4/18/2016
  • Box: Biosimilars battles

    Can 'Cures' be cured? Biosimilars battles An arcane phrase inserted into part of the Senate Cures legislative package has set off alarm bells at some biosimilar companies and in the offices of the U.S. …

    Published on 4/18/2016
  • Box: Concentrating power at NIH

    Can 'Cures' be cured? Concentrating power at NIH The NIH provisions of the House and Senate's Cures legislation seek to make NIH more accountable, but they do this by aggregating more money and power in the hands …

    Published on 4/18/2016
  • Figure: 21st Century Cures

    Can 'Cures' be cured? 21st Century Cures The U.S. House of Representatives voted 344 -77 on July 10, 2015 to pass the 21st Century Cures Act (H.R. 6). Selected provisions of the 362-page bill follow, some of which…

    Published on 4/18/2016
  • Table: Senate innovation agenda

    Can 'Cures' be cured? Senate innovation agenda The Senate Health, Education, Labor and Pensions (HELP) Committee has passed a series of bills that Chair Lamar Alexander (R-Tenn.) intends to bundle into a single …

    Published on 4/18/2016
  • Box: Bristol's I/O network

    Survive and advance Bristol's I/O network In 2012, Bristol-Myers Squibb Co. established the International Immuno-Oncology Network (II-ON), a public-private partnership that includes 13 immuno-oncology universities…

    Published on 4/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993